Brian Day
Concepts (579)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antioxidants | 46 | 2024 | 584 | 6.030 |
Why?
| | Glutathione | 31 | 2024 | 356 | 5.270 |
Why?
| | Oxidative Stress | 44 | 2024 | 1317 | 4.160 |
Why?
| | Metalloporphyrins | 27 | 2024 | 103 | 3.840 |
Why?
| | Mustard Gas | 8 | 2024 | 103 | 2.440 |
Why?
| | Thiocyanates | 6 | 2019 | 31 | 1.930 |
Why?
| | Bronchoalveolar Lavage Fluid | 15 | 2021 | 652 | 1.810 |
Why?
| | Chemical Warfare Agents | 5 | 2024 | 114 | 1.770 |
Why?
| | Lung | 24 | 2025 | 4060 | 1.750 |
Why?
| | Reactive Oxygen Species | 22 | 2018 | 622 | 1.640 |
Why?
| | Lung Injury | 5 | 2024 | 219 | 1.610 |
Why?
| | Particulate Matter | 4 | 2021 | 315 | 1.430 |
Why?
| | ATP-Binding Cassette Transporters | 5 | 2012 | 137 | 1.300 |
Why?
| | Smoking | 9 | 2015 | 1627 | 1.090 |
Why?
| | Immunity, Innate | 3 | 2019 | 828 | 0.970 |
Why?
| | Antidotes | 3 | 2016 | 143 | 0.910 |
Why?
| | Mesalamine | 2 | 2017 | 10 | 0.890 |
Why?
| | Lung Diseases | 4 | 2021 | 767 | 0.890 |
Why?
| | Flavonoids | 3 | 2011 | 85 | 0.860 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2012 | 329 | 0.860 |
Why?
| | Berylliosis | 4 | 2017 | 186 | 0.850 |
Why?
| | Animals | 72 | 2024 | 36940 | 0.810 |
Why?
| | Tumor Necrosis Factor-alpha | 7 | 2023 | 1242 | 0.800 |
Why?
| | Inflammation | 11 | 2020 | 2837 | 0.800 |
Why?
| | Superoxide Dismutase | 13 | 2015 | 346 | 0.790 |
Why?
| | Cystic Fibrosis | 4 | 2020 | 1114 | 0.780 |
Why?
| | Pneumonia | 2 | 2020 | 639 | 0.770 |
Why?
| | Mitochondria | 11 | 2015 | 948 | 0.750 |
Why?
| | Molecular Mimicry | 3 | 2008 | 42 | 0.700 |
Why?
| | Acetylcysteine | 5 | 2016 | 145 | 0.680 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2020 | 26 | 0.670 |
Why?
| | Inhalation Exposure | 5 | 2016 | 105 | 0.670 |
Why?
| | Interleukin-33 | 1 | 2020 | 50 | 0.660 |
Why?
| | Epithelial Cells | 10 | 2025 | 1096 | 0.660 |
Why?
| | Thioredoxin-Disulfide Reductase | 3 | 2015 | 13 | 0.650 |
Why?
| | Anti-Infective Agents | 2 | 2019 | 255 | 0.650 |
Why?
| | Oxidation-Reduction | 14 | 2017 | 1060 | 0.620 |
Why?
| | Prodrugs | 1 | 2019 | 52 | 0.620 |
Why?
| | Chalcones | 5 | 2012 | 7 | 0.620 |
Why?
| | Neuroprotective Agents | 5 | 2021 | 131 | 0.610 |
Why?
| | Neoplasm Proteins | 4 | 2014 | 434 | 0.610 |
Why?
| | Influenza A virus | 3 | 2025 | 107 | 0.580 |
Why?
| | Deoxyguanosine | 4 | 2016 | 25 | 0.580 |
Why?
| | Inflammation Mediators | 5 | 2018 | 513 | 0.570 |
Why?
| | Mice | 37 | 2021 | 17787 | 0.570 |
Why?
| | Allergens | 1 | 2021 | 409 | 0.570 |
Why?
| | Beryllium | 3 | 2009 | 153 | 0.560 |
Why?
| | Anti-Bacterial Agents | 3 | 2019 | 1809 | 0.530 |
Why?
| | Electronic Nicotine Delivery Systems | 3 | 2023 | 103 | 0.530 |
Why?
| | Manganese | 5 | 2024 | 62 | 0.530 |
Why?
| | Cell Line | 13 | 2020 | 2847 | 0.530 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 234 | 0.520 |
Why?
| | Organometallic Compounds | 2 | 2009 | 111 | 0.510 |
Why?
| | Free Radical Scavengers | 6 | 2013 | 88 | 0.510 |
Why?
| | Wound Healing | 1 | 2019 | 331 | 0.500 |
Why?
| | Catalase | 4 | 2013 | 130 | 0.500 |
Why?
| | Status Epilepticus | 4 | 2024 | 50 | 0.500 |
Why?
| | Industrial Waste | 1 | 2015 | 6 | 0.490 |
Why?
| | War Exposure | 1 | 2015 | 12 | 0.490 |
Why?
| | Immunity, Cellular | 1 | 2017 | 268 | 0.490 |
Why?
| | Reverse Transcriptase Inhibitors | 3 | 2004 | 84 | 0.480 |
Why?
| | Mice, Inbred C57BL | 18 | 2021 | 5757 | 0.470 |
Why?
| | Peroxidases | 1 | 2015 | 34 | 0.460 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2016 | 83 | 0.460 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 350 | 0.450 |
Why?
| | Respiratory Mucosa | 4 | 2011 | 321 | 0.440 |
Why?
| | Lymphocytes | 3 | 2017 | 397 | 0.440 |
Why?
| | NF-E2-Related Factor 2 | 2 | 2013 | 93 | 0.440 |
Why?
| | Respiratory System | 1 | 2015 | 157 | 0.430 |
Why?
| | Afghanistan | 4 | 2021 | 71 | 0.430 |
Why?
| | Skin | 3 | 2014 | 752 | 0.430 |
Why?
| | DNA, Mitochondrial | 5 | 2009 | 200 | 0.420 |
Why?
| | Rats, Sprague-Dawley | 15 | 2024 | 2486 | 0.410 |
Why?
| | Rats | 20 | 2024 | 5647 | 0.410 |
Why?
| | Influenza, Human | 3 | 2025 | 622 | 0.400 |
Why?
| | Cell Survival | 8 | 2014 | 1120 | 0.400 |
Why?
| | Macrophages, Alveolar | 3 | 2011 | 391 | 0.400 |
Why?
| | Cytokines | 8 | 2018 | 2085 | 0.390 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2025 | 1040 | 0.390 |
Why?
| | Cell Proliferation | 6 | 2017 | 2475 | 0.380 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2012 | 11 | 0.380 |
Why?
| | Chemokines, CC | 1 | 2012 | 33 | 0.370 |
Why?
| | Pinocytosis | 1 | 2011 | 11 | 0.370 |
Why?
| | Glutathione Peroxidase | 2 | 2008 | 43 | 0.370 |
Why?
| | Humans | 57 | 2025 | 137585 | 0.370 |
Why?
| | DNA | 4 | 2016 | 1459 | 0.370 |
Why?
| | Smoke | 3 | 2013 | 141 | 0.370 |
Why?
| | Nerve Agents | 2 | 2024 | 7 | 0.370 |
Why?
| | Extracellular Space | 2 | 2011 | 119 | 0.370 |
Why?
| | Chalcone | 1 | 2011 | 2 | 0.370 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 496 | 0.370 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2011 | 162 | 0.360 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2011 | 127 | 0.360 |
Why?
| | Macrophages | 6 | 2020 | 1547 | 0.350 |
Why?
| | Oxidants | 5 | 2019 | 111 | 0.350 |
Why?
| | Environmental Exposure | 1 | 2015 | 579 | 0.340 |
Why?
| | Membrane Transport Proteins | 1 | 2012 | 162 | 0.340 |
Why?
| | Adaptation, Physiological | 2 | 2011 | 553 | 0.340 |
Why?
| | Virus Diseases | 2 | 2023 | 212 | 0.330 |
Why?
| | Macrophage Activation | 1 | 2011 | 201 | 0.330 |
Why?
| | Doxorubicin | 2 | 2011 | 362 | 0.330 |
Why?
| | Sulfasalazine | 1 | 2009 | 23 | 0.320 |
Why?
| | Mitochondria, Liver | 3 | 2004 | 73 | 0.320 |
Why?
| | Chelating Agents | 1 | 2009 | 75 | 0.320 |
Why?
| | Prostaglandin D2 | 1 | 2009 | 23 | 0.310 |
Why?
| | Mitochondrial Diseases | 1 | 2009 | 91 | 0.300 |
Why?
| | Lung Neoplasms | 4 | 2011 | 2526 | 0.300 |
Why?
| | Male | 40 | 2025 | 67762 | 0.300 |
Why?
| | Mitochondrial Membranes | 1 | 2008 | 39 | 0.300 |
Why?
| | Adenosine Triphosphate | 2 | 2015 | 491 | 0.300 |
Why?
| | Cell Line, Tumor | 8 | 2012 | 3412 | 0.290 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 225 | 0.290 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 2 | 2005 | 11 | 0.290 |
Why?
| | Mycoplasma pneumoniae | 1 | 2008 | 57 | 0.290 |
Why?
| | Mice, Inbred CFTR | 4 | 2012 | 5 | 0.280 |
Why?
| | Apoptosis | 9 | 2015 | 2553 | 0.280 |
Why?
| | Chlorine | 3 | 2015 | 61 | 0.280 |
Why?
| | Lymphocyte Activation | 3 | 2009 | 1142 | 0.280 |
Why?
| | Gene Expression Regulation | 4 | 2020 | 2607 | 0.280 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2011 | 597 | 0.270 |
Why?
| | Peroxidase | 4 | 2020 | 175 | 0.270 |
Why?
| | Hippocampus | 5 | 2024 | 895 | 0.250 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2011 | 801 | 0.250 |
Why?
| | Disease Models, Animal | 13 | 2024 | 4295 | 0.250 |
Why?
| | Carrier Proteins | 1 | 2010 | 771 | 0.240 |
Why?
| | Chronic Disease | 7 | 2017 | 1793 | 0.240 |
Why?
| | Administration, Oral | 5 | 2021 | 816 | 0.240 |
Why?
| | Cisplatin | 1 | 2007 | 320 | 0.230 |
Why?
| | Hydrogen Peroxide | 5 | 2012 | 328 | 0.230 |
Why?
| | Epilepsy, Temporal Lobe | 2 | 2015 | 38 | 0.230 |
Why?
| | Microsomes, Liver | 1 | 2005 | 86 | 0.230 |
Why?
| | Stavudine | 1 | 2004 | 8 | 0.230 |
Why?
| | Monocytes | 2 | 2021 | 563 | 0.230 |
Why?
| | Mice, Knockout | 10 | 2015 | 3015 | 0.230 |
Why?
| | Neoplasms | 3 | 2014 | 2671 | 0.220 |
Why?
| | Flavins | 1 | 2004 | 3 | 0.220 |
Why?
| | Pulmonary Fibrosis | 1 | 2008 | 402 | 0.220 |
Why?
| | Nucleosides | 1 | 2004 | 27 | 0.210 |
Why?
| | Lipid Peroxidation | 7 | 2007 | 153 | 0.210 |
Why?
| | Glutamate-Cysteine Ligase | 3 | 2024 | 20 | 0.210 |
Why?
| | Head and Neck Neoplasms | 1 | 2009 | 606 | 0.210 |
Why?
| | Cigarette Smoking | 1 | 2025 | 101 | 0.210 |
Why?
| | Pulmonary Edema | 1 | 2003 | 108 | 0.200 |
Why?
| | Bronchoalveolar Lavage | 2 | 2021 | 93 | 0.200 |
Why?
| | DNA Replication | 1 | 2004 | 238 | 0.200 |
Why?
| | Anticonvulsants | 2 | 2017 | 217 | 0.190 |
Why?
| | Cells, Cultured | 8 | 2018 | 4193 | 0.190 |
Why?
| | Vaping | 1 | 2023 | 60 | 0.190 |
Why?
| | Signal Transduction | 6 | 2020 | 5079 | 0.190 |
Why?
| | Brain | 4 | 2018 | 2668 | 0.190 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2002 | 86 | 0.190 |
Why?
| | Electrochemistry | 1 | 2002 | 78 | 0.190 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2025 | 455 | 0.190 |
Why?
| | Double-Blind Method | 2 | 2017 | 1993 | 0.190 |
Why?
| | Lipopolysaccharides | 4 | 2016 | 886 | 0.180 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2008 | 1091 | 0.180 |
Why?
| | Substrate Specificity | 3 | 2013 | 372 | 0.180 |
Why?
| | Structure-Activity Relationship | 5 | 2012 | 570 | 0.180 |
Why?
| | Pulmonary Alveoli | 2 | 2020 | 405 | 0.180 |
Why?
| | Administration, Inhalation | 3 | 2015 | 688 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2016 | 2057 | 0.170 |
Why?
| | Thiobarbituric Acid Reactive Substances | 4 | 2007 | 30 | 0.170 |
Why?
| | Oxygen | 4 | 2015 | 931 | 0.170 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 35 | 0.170 |
Why?
| | Aging | 2 | 2010 | 1864 | 0.170 |
Why?
| | Burkholderia | 1 | 2020 | 12 | 0.170 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2129 | 0.160 |
Why?
| | Adenocarcinoma | 1 | 2007 | 940 | 0.160 |
Why?
| | Cyanates | 1 | 2019 | 4 | 0.160 |
Why?
| | Middle Aged | 11 | 2025 | 33479 | 0.160 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2017 | 184 | 0.160 |
Why?
| | Selenium Compounds | 1 | 2019 | 21 | 0.160 |
Why?
| | MPTP Poisoning | 2 | 2017 | 6 | 0.150 |
Why?
| | Mice, Hairless | 3 | 2014 | 60 | 0.150 |
Why?
| | Particle Size | 1 | 2020 | 394 | 0.150 |
Why?
| | Morbidity | 1 | 2020 | 324 | 0.150 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 452 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 383 | 0.150 |
Why?
| | Isoflurophate | 1 | 2018 | 9 | 0.150 |
Why?
| | Drug Synergism | 3 | 2012 | 382 | 0.140 |
Why?
| | Female | 20 | 2025 | 73304 | 0.140 |
Why?
| | DNA Damage | 5 | 2009 | 420 | 0.140 |
Why?
| | Neurotoxicity Syndromes | 1 | 2018 | 25 | 0.140 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 352 | 0.140 |
Why?
| | Interleukin-13 | 1 | 2018 | 149 | 0.140 |
Why?
| | Dimercaprol | 1 | 2017 | 6 | 0.140 |
Why?
| | Neutrophils | 3 | 2020 | 1238 | 0.130 |
Why?
| | Antiparkinson Agents | 1 | 2017 | 27 | 0.130 |
Why?
| | Kinetics | 2 | 2013 | 1670 | 0.130 |
Why?
| | Catalysis | 3 | 2008 | 307 | 0.130 |
Why?
| | Auranofin | 2 | 2013 | 9 | 0.130 |
Why?
| | Reactive Nitrogen Species | 2 | 2018 | 21 | 0.130 |
Why?
| | Tumor Cells, Cultured | 2 | 2011 | 955 | 0.130 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2007 | 100 | 0.130 |
Why?
| | Sulfhydryl Compounds | 2 | 2017 | 189 | 0.120 |
Why?
| | Cornea | 2 | 2007 | 138 | 0.120 |
Why?
| | Age Factors | 2 | 2015 | 3295 | 0.120 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2015 | 38 | 0.120 |
Why?
| | Myocardium | 4 | 2015 | 1002 | 0.120 |
Why?
| | Aged | 6 | 2018 | 23961 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 558 | 0.110 |
Why?
| | Intracellular Space | 2 | 2012 | 68 | 0.110 |
Why?
| | Matrix Metalloproteinases | 1 | 2015 | 95 | 0.110 |
Why?
| | Thiourea | 2 | 2013 | 40 | 0.110 |
Why?
| | NADPH Oxidases | 2 | 2013 | 113 | 0.110 |
Why?
| | Comet Assay | 1 | 2014 | 16 | 0.110 |
Why?
| | Neurons | 3 | 2018 | 1590 | 0.110 |
Why?
| | Drug Resistance, Multiple | 1 | 2014 | 25 | 0.110 |
Why?
| | Mice, Inbred BALB C | 4 | 2013 | 1272 | 0.110 |
Why?
| | Response Elements | 2 | 2012 | 91 | 0.110 |
Why?
| | Pneumonia, Bacterial | 1 | 2015 | 116 | 0.110 |
Why?
| | DNA-Directed DNA Polymerase | 2 | 2006 | 44 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 101 | 0.110 |
Why?
| | Transcription Factor AP-1 | 2 | 2011 | 92 | 0.110 |
Why?
| | Selenocysteine | 1 | 2013 | 4 | 0.100 |
Why?
| | Pollen | 1 | 2013 | 21 | 0.100 |
Why?
| | Cytoprotection | 2 | 2013 | 56 | 0.100 |
Why?
| | Hypochlorous Acid | 1 | 2013 | 8 | 0.100 |
Why?
| | Bronchioles | 1 | 2013 | 23 | 0.100 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2013 | 45 | 0.100 |
Why?
| | Adult | 8 | 2016 | 37929 | 0.100 |
Why?
| | Thioredoxin Reductase 2 | 1 | 2012 | 2 | 0.100 |
Why?
| | Glycolysis | 1 | 2015 | 321 | 0.100 |
Why?
| | Liver | 4 | 2024 | 1943 | 0.100 |
Why?
| | Microbial Viability | 1 | 2013 | 91 | 0.100 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2010 | 122 | 0.100 |
Why?
| | In Vitro Techniques | 2 | 2005 | 1092 | 0.100 |
Why?
| | MAP Kinase Signaling System | 2 | 2017 | 320 | 0.100 |
Why?
| | Antigens | 1 | 2014 | 357 | 0.100 |
Why?
| | Immunohistochemistry | 4 | 2010 | 1738 | 0.100 |
Why?
| | Bacteria | 1 | 2019 | 858 | 0.100 |
Why?
| | Alveolar Epithelial Cells | 1 | 2013 | 114 | 0.090 |
Why?
| | Biomarkers | 5 | 2018 | 4149 | 0.090 |
Why?
| | Random Allocation | 4 | 2017 | 353 | 0.090 |
Why?
| | Dopaminergic Neurons | 1 | 2012 | 69 | 0.090 |
Why?
| | Amino Acid Substitution | 1 | 2013 | 307 | 0.090 |
Why?
| | Transcriptional Activation | 2 | 2011 | 378 | 0.090 |
Why?
| | Cysteine | 1 | 2013 | 204 | 0.090 |
Why?
| | Ischemia | 2 | 2007 | 409 | 0.090 |
Why?
| | Extracellular Fluid | 1 | 2011 | 31 | 0.090 |
Why?
| | Heart Diseases | 1 | 2015 | 346 | 0.090 |
Why?
| | Olfactory Mucosa | 1 | 2011 | 38 | 0.090 |
Why?
| | Antigen-Presenting Cells | 2 | 2009 | 156 | 0.090 |
Why?
| | Cognition Disorders | 1 | 2015 | 496 | 0.090 |
Why?
| | Copper | 2 | 2009 | 104 | 0.090 |
Why?
| | Fumarate Hydratase | 2 | 2011 | 3 | 0.090 |
Why?
| | Aconitate Hydratase | 2 | 2011 | 17 | 0.090 |
Why?
| | Mitochondria, Heart | 3 | 2015 | 102 | 0.090 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 273 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 411 | 0.090 |
Why?
| | Blue Cross Blue Shield Insurance Plans | 1 | 2010 | 2 | 0.090 |
Why?
| | Nasal Cavity | 1 | 2011 | 52 | 0.090 |
Why?
| | Phagocytosis | 2 | 2012 | 380 | 0.090 |
Why?
| | Blood-Brain Barrier | 3 | 2021 | 138 | 0.090 |
Why?
| | Irritants | 1 | 2010 | 43 | 0.080 |
Why?
| | Cardiomyopathies | 2 | 2006 | 350 | 0.080 |
Why?
| | Bronchi | 1 | 2012 | 260 | 0.080 |
Why?
| | Peptide Fragments | 1 | 2014 | 706 | 0.080 |
Why?
| | Apoproteins | 1 | 2009 | 15 | 0.080 |
Why?
| | Asthma | 3 | 2013 | 2295 | 0.080 |
Why?
| | Dopamine | 2 | 2017 | 303 | 0.080 |
Why?
| | HIV Infections | 2 | 2004 | 2836 | 0.080 |
Why?
| | Dermatitis, Irritant | 1 | 2009 | 10 | 0.080 |
Why?
| | Fluorescent Dyes | 1 | 2011 | 321 | 0.080 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 64 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 409 | 0.080 |
Why?
| | tert-Butylhydroperoxide | 1 | 2009 | 10 | 0.080 |
Why?
| | Fungal Proteins | 1 | 2010 | 123 | 0.080 |
Why?
| | Electron Transport | 1 | 2009 | 115 | 0.080 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2009 | 95 | 0.080 |
Why?
| | Iron | 2 | 2009 | 313 | 0.080 |
Why?
| | Paraquat | 2 | 2012 | 14 | 0.080 |
Why?
| | Health Expenditures | 1 | 2010 | 189 | 0.080 |
Why?
| | Biological Transport | 1 | 2010 | 418 | 0.080 |
Why?
| | Demography | 1 | 2009 | 291 | 0.080 |
Why?
| | Biocatalysis | 1 | 2008 | 56 | 0.070 |
Why?
| | rho GTP-Binding Proteins | 1 | 2009 | 60 | 0.070 |
Why?
| | Amino Acids | 2 | 2010 | 497 | 0.070 |
Why?
| | Body Fluids | 1 | 2008 | 66 | 0.070 |
Why?
| | Interferon-gamma | 2 | 2009 | 789 | 0.070 |
Why?
| | Time Factors | 3 | 2016 | 6828 | 0.070 |
Why?
| | Benzimidazoles | 1 | 2009 | 170 | 0.070 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2008 | 57 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2003 | 1946 | 0.070 |
Why?
| | Self Care | 1 | 2010 | 380 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 976 | 0.070 |
Why?
| | Epilepsy | 1 | 2011 | 333 | 0.070 |
Why?
| | Gene Expression | 3 | 2013 | 1502 | 0.070 |
Why?
| | Electron Transport Complex I | 1 | 2007 | 41 | 0.070 |
Why?
| | Neurofibromin 1 | 1 | 2007 | 26 | 0.070 |
Why?
| | Radiation-Protective Agents | 1 | 2007 | 26 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 767 | 0.070 |
Why?
| | Radiation Injuries, Experimental | 1 | 2007 | 22 | 0.070 |
Why?
| | Bacterial Proteins | 1 | 2013 | 879 | 0.070 |
Why?
| | Eye Proteins | 1 | 2007 | 92 | 0.070 |
Why?
| | Antiviral Agents | 2 | 2023 | 744 | 0.070 |
Why?
| | Intestinal Absorption | 1 | 2007 | 102 | 0.060 |
Why?
| | Neurofibromatosis 1 | 1 | 2007 | 52 | 0.060 |
Why?
| | Fibrosis | 1 | 2009 | 552 | 0.060 |
Why?
| | Cell Fractionation | 1 | 2006 | 56 | 0.060 |
Why?
| | Pilocarpine | 2 | 2017 | 15 | 0.060 |
Why?
| | HL-60 Cells | 1 | 2006 | 34 | 0.060 |
Why?
| | Disease Management | 1 | 2010 | 628 | 0.060 |
Why?
| | Dexamethasone | 2 | 2012 | 368 | 0.060 |
Why?
| | Mycoplasma Infections | 1 | 2006 | 16 | 0.060 |
Why?
| | Stromal Cells | 1 | 2006 | 112 | 0.060 |
Why?
| | Leukemia, Myeloid | 1 | 2006 | 45 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2009 | 1178 | 0.060 |
Why?
| | Lens, Crystalline | 1 | 2007 | 125 | 0.060 |
Why?
| | Radiation Injuries | 1 | 2007 | 145 | 0.060 |
Why?
| | Quality of Life | 1 | 2017 | 2892 | 0.060 |
Why?
| | Longevity | 1 | 2007 | 165 | 0.060 |
Why?
| | Corpus Striatum | 1 | 2007 | 167 | 0.060 |
Why?
| | Young Adult | 3 | 2023 | 13209 | 0.060 |
Why?
| | Saccharomyces cerevisiae | 1 | 2010 | 557 | 0.060 |
Why?
| | Cytochrome P-450 CYP2B1 | 1 | 2005 | 1 | 0.060 |
Why?
| | Caspase 8 | 1 | 2005 | 48 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 2005 | 10 | 0.060 |
Why?
| | Models, Biological | 2 | 2010 | 1783 | 0.060 |
Why?
| | Drosophila melanogaster | 1 | 2007 | 233 | 0.060 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 51 | 0.060 |
Why?
| | Xenobiotics | 1 | 2005 | 32 | 0.060 |
Why?
| | Cations | 1 | 2005 | 84 | 0.060 |
Why?
| | Aldehydes | 3 | 2012 | 145 | 0.060 |
Why?
| | Nitric Oxide Synthase | 2 | 2003 | 240 | 0.060 |
Why?
| | Oxidoreductases | 1 | 2005 | 92 | 0.060 |
Why?
| | Cysteamine | 1 | 2024 | 8 | 0.060 |
Why?
| | Cataract | 1 | 2007 | 213 | 0.060 |
Why?
| | Ferritins | 1 | 2004 | 64 | 0.060 |
Why?
| | Reperfusion Injury | 1 | 2007 | 279 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2005 | 155 | 0.050 |
Why?
| | Caspases | 1 | 2005 | 247 | 0.050 |
Why?
| | Cell Respiration | 2 | 2015 | 103 | 0.050 |
Why?
| | Liver Diseases | 1 | 2007 | 315 | 0.050 |
Why?
| | Glyoxylates | 1 | 2003 | 10 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2018 | 622 | 0.050 |
Why?
| | Insulin | 1 | 2014 | 2409 | 0.050 |
Why?
| | Sulfonylurea Compounds | 1 | 2003 | 48 | 0.050 |
Why?
| | Hypertension | 1 | 2012 | 1295 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1396 | 0.050 |
Why?
| | Liver Circulation | 1 | 2002 | 20 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 134 | 0.050 |
Why?
| | Half-Life | 2 | 2017 | 164 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2003 | 329 | 0.050 |
Why?
| | Adolescent | 3 | 2023 | 21513 | 0.050 |
Why?
| | Probability | 1 | 2003 | 304 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 431 | 0.050 |
Why?
| | Disease Progression | 1 | 2010 | 2757 | 0.050 |
Why?
| | Down-Regulation | 1 | 2025 | 657 | 0.050 |
Why?
| | Cell Death | 2 | 2015 | 374 | 0.050 |
Why?
| | Gene Products, tat | 1 | 2002 | 23 | 0.050 |
Why?
| | Hemin | 1 | 2002 | 4 | 0.050 |
Why?
| | Endotoxemia | 1 | 2003 | 86 | 0.050 |
Why?
| | Nitric Acid | 1 | 2002 | 5 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 152 | 0.050 |
Why?
| | Molecular Structure | 1 | 2003 | 489 | 0.050 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 271 | 0.050 |
Why?
| | Iraq | 1 | 2021 | 53 | 0.050 |
Why?
| | Reference Values | 1 | 2003 | 816 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1353 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2003 | 226 | 0.050 |
Why?
| | Polymerase Chain Reaction | 1 | 2004 | 1062 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2003 | 522 | 0.040 |
Why?
| | Blotting, Western | 3 | 2011 | 1226 | 0.040 |
Why?
| | Parkinson Disease | 1 | 2007 | 493 | 0.040 |
Why?
| | Epithelium | 1 | 2022 | 313 | 0.040 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2004 | 362 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2023 | 286 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2021 | 332 | 0.040 |
Why?
| | Eosinophils | 1 | 2003 | 332 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 660 | 0.040 |
Why?
| | Glutathione Disulfide | 2 | 2011 | 33 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2017 | 810 | 0.040 |
Why?
| | Estrogens | 1 | 2002 | 367 | 0.040 |
Why?
| | Obesity | 1 | 2012 | 2992 | 0.040 |
Why?
| | Soman | 1 | 2018 | 2 | 0.040 |
Why?
| | Brain Ischemia | 1 | 2002 | 338 | 0.040 |
Why?
| | Bronchial Diseases | 1 | 2018 | 37 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 1050 | 0.040 |
Why?
| | Tyrosine | 2 | 2011 | 222 | 0.040 |
Why?
| | Blood Pressure | 2 | 2003 | 1786 | 0.040 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 30 | 0.040 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 641 | 0.040 |
Why?
| | Cohort Studies | 2 | 2012 | 5742 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 1043 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2018 | 199 | 0.040 |
Why?
| | Toll-Like Receptor 2 | 1 | 2018 | 115 | 0.040 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2003 | 383 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2003 | 827 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2003 | 915 | 0.030 |
Why?
| | Interleukin-8 | 1 | 2018 | 268 | 0.030 |
Why?
| | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2017 | 3 | 0.030 |
Why?
| | Mice, Inbred NOD | 2 | 2014 | 601 | 0.030 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 16 | 0.030 |
Why?
| | Hemodynamics | 1 | 2002 | 1113 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2011 | 173 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 2017 | 114 | 0.030 |
Why?
| | Transfection | 2 | 2012 | 945 | 0.030 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1996 | 0.030 |
Why?
| | Biological Availability | 1 | 2017 | 148 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1692 | 0.030 |
Why?
| | Nervous System | 1 | 2017 | 67 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2017 | 145 | 0.030 |
Why?
| | Proteins | 1 | 2003 | 1009 | 0.030 |
Why?
| | RNA | 1 | 2023 | 921 | 0.030 |
Why?
| | Microglia | 1 | 2018 | 251 | 0.030 |
Why?
| | Drug Design | 1 | 2017 | 167 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2003 | 3556 | 0.030 |
Why?
| | Etiocholanolone | 1 | 2015 | 6 | 0.030 |
Why?
| | Nootropic Agents | 1 | 2015 | 27 | 0.030 |
Why?
| | Ranolazine | 1 | 2015 | 25 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2002 | 927 | 0.030 |
Why?
| | Kainic Acid | 1 | 2015 | 35 | 0.030 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 840 | 0.030 |
Why?
| | Acute Kidney Injury | 1 | 2003 | 815 | 0.030 |
Why?
| | Military Personnel | 1 | 2021 | 544 | 0.030 |
Why?
| | Prognosis | 1 | 2003 | 4030 | 0.030 |
Why?
| | DNA Polymerase gamma | 2 | 2006 | 8 | 0.030 |
Why?
| | RNA, Messenger | 3 | 2012 | 2833 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 124 | 0.030 |
Why?
| | Alanine Transaminase | 2 | 2007 | 157 | 0.030 |
Why?
| | Dimerization | 1 | 2014 | 199 | 0.030 |
Why?
| | Betula | 1 | 2013 | 3 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2017 | 501 | 0.030 |
Why?
| | Echocardiography | 2 | 2009 | 642 | 0.030 |
Why?
| | Oxidopamine | 1 | 2012 | 17 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2008 | 10811 | 0.030 |
Why?
| | PPAR delta | 1 | 2012 | 5 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2015 | 249 | 0.030 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2012 | 26 | 0.030 |
Why?
| | Peroxiredoxins | 1 | 2012 | 24 | 0.020 |
Why?
| | Interferon-beta | 1 | 2013 | 92 | 0.020 |
Why?
| | Receptors, Chemokine | 1 | 2012 | 47 | 0.020 |
Why?
| | Lentivirus | 1 | 2012 | 56 | 0.020 |
Why?
| | Papio | 2 | 2003 | 94 | 0.020 |
Why?
| | Mesencephalon | 1 | 2012 | 66 | 0.020 |
Why?
| | NF-E2 Transcription Factor, p45 Subunit | 1 | 2012 | 3 | 0.020 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2012 | 19 | 0.020 |
Why?
| | Emphysema | 1 | 2013 | 106 | 0.020 |
Why?
| | Th2 Cells | 1 | 2013 | 176 | 0.020 |
Why?
| | Coenzyme A | 1 | 2011 | 7 | 0.020 |
Why?
| | Holoenzymes | 1 | 2012 | 24 | 0.020 |
Why?
| | Motor Activity | 1 | 2017 | 718 | 0.020 |
Why?
| | Adenine Nucleotides | 1 | 2011 | 23 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1007 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 150 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 327 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2014 | 3715 | 0.020 |
Why?
| | NAD | 1 | 2011 | 77 | 0.020 |
Why?
| | Cell Division | 2 | 2004 | 794 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2004 | 2111 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2012 | 269 | 0.020 |
Why?
| | Receptors, Glucocorticoid | 1 | 2012 | 155 | 0.020 |
Why?
| | Prospective Studies | 1 | 2003 | 7604 | 0.020 |
Why?
| | Buthionine Sulfoximine | 1 | 2010 | 9 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 219 | 0.020 |
Why?
| | Dermatitis | 1 | 2010 | 20 | 0.020 |
Why?
| | Skinfold Thickness | 1 | 2010 | 46 | 0.020 |
Why?
| | Sputum | 1 | 2012 | 311 | 0.020 |
Why?
| | Pennsylvania | 1 | 2010 | 116 | 0.020 |
Why?
| | Myocytes, Cardiac | 1 | 2015 | 526 | 0.020 |
Why?
| | Insurance Claim Review | 1 | 2010 | 64 | 0.020 |
Why?
| | Deoxyadenosines | 1 | 2009 | 9 | 0.020 |
Why?
| | Oncogene Protein v-akt | 1 | 2009 | 24 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2009 | 29 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 730 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 844 | 0.020 |
Why?
| | Oxygen Consumption | 2 | 2002 | 696 | 0.020 |
Why?
| | Fibroblasts | 2 | 2006 | 996 | 0.020 |
Why?
| | Electroencephalography | 1 | 2011 | 423 | 0.020 |
Why?
| | Heart Ventricles | 2 | 2006 | 788 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2009 | 119 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1316 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 412 | 0.020 |
Why?
| | Mice, Transgenic | 2 | 2006 | 2167 | 0.020 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2009 | 86 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2009 | 131 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 600 | 0.020 |
Why?
| | Oxidative Phosphorylation | 1 | 2009 | 193 | 0.020 |
Why?
| | Phenotype | 2 | 2007 | 3196 | 0.020 |
Why?
| | rho-Associated Kinases | 1 | 2009 | 83 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 2011 | 433 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2012 | 594 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2010 | 591 | 0.020 |
Why?
| | Cell Cycle | 1 | 2010 | 601 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2007 | 29 | 0.020 |
Why?
| | Nitrosation | 1 | 2007 | 8 | 0.020 |
Why?
| | Membrane Lipids | 1 | 2007 | 91 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2007 | 157 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1570 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2007 | 90 | 0.020 |
Why?
| | Mitomycin | 1 | 2006 | 34 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2012 | 922 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 2007 | 265 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 156 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 324 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2007 | 234 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2007 | 240 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 2006 | 46 | 0.020 |
Why?
| | Etoposide | 1 | 2006 | 158 | 0.020 |
Why?
| | Internet | 1 | 2010 | 655 | 0.020 |
Why?
| | Protein Binding | 2 | 2002 | 2224 | 0.020 |
Why?
| | NF-kappa B | 1 | 2009 | 691 | 0.010 |
Why?
| | Heart | 1 | 2009 | 655 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1457 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 786 | 0.010 |
Why?
| | Rabbits | 1 | 2006 | 794 | 0.010 |
Why?
| | Radioisotopes | 1 | 2004 | 31 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 396 | 0.010 |
Why?
| | fas Receptor | 1 | 2004 | 95 | 0.010 |
Why?
| | Phagocytes | 1 | 2004 | 101 | 0.010 |
Why?
| | Renal Blood Flow, Effective | 1 | 2003 | 2 | 0.010 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 1 | 2003 | 12 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2004 | 218 | 0.010 |
Why?
| | Mutation | 2 | 2006 | 3958 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2003 | 82 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 385 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 2002 | 55 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2003 | 84 | 0.010 |
Why?
| | DNA Polymerase beta | 1 | 2002 | 5 | 0.010 |
Why?
| | Kupffer Cells | 1 | 2002 | 50 | 0.010 |
Why?
| | Guinea Pigs | 1 | 2002 | 158 | 0.010 |
Why?
| | Cerebral Infarction | 1 | 2002 | 44 | 0.010 |
Why?
| | Carotid Artery, Internal | 1 | 2002 | 42 | 0.010 |
Why?
| | Permeability | 1 | 2003 | 161 | 0.010 |
Why?
| | Estrone | 1 | 2002 | 37 | 0.010 |
Why?
| | DNA Polymerase I | 1 | 2002 | 29 | 0.010 |
Why?
| | Linoleic Acid | 1 | 2002 | 43 | 0.010 |
Why?
| | Ions | 1 | 2002 | 70 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 2002 | 57 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2002 | 16 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2002 | 145 | 0.010 |
Why?
| | Isoelectric Focusing | 1 | 2002 | 34 | 0.010 |
Why?
| | S-Nitrosoglutathione | 1 | 2002 | 8 | 0.010 |
Why?
| | PC12 Cells | 1 | 2002 | 40 | 0.010 |
Why?
| | Insulinoma | 1 | 2002 | 26 | 0.010 |
Why?
| | Gene Targeting | 1 | 2002 | 81 | 0.010 |
Why?
| | Free Radicals | 1 | 2002 | 110 | 0.010 |
Why?
| | Electrons | 1 | 2002 | 83 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2003 | 284 | 0.010 |
Why?
| | Hyperoxia | 1 | 2003 | 90 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 443 | 0.010 |
Why?
| | Dogs | 1 | 2002 | 413 | 0.010 |
Why?
| | Clone Cells | 1 | 2002 | 265 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 305 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2002 | 224 | 0.010 |
Why?
| | Hormone Replacement Therapy | 1 | 2002 | 100 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 148 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 313 | 0.010 |
Why?
| | Mice, SCID | 1 | 2002 | 367 | 0.010 |
Why?
| | Hepatectomy | 1 | 2002 | 251 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 2002 | 150 | 0.010 |
Why?
| | Models, Chemical | 1 | 2002 | 263 | 0.010 |
Why?
| | Ascorbic Acid | 1 | 2002 | 177 | 0.010 |
Why?
| | Myocardial Contraction | 1 | 2002 | 341 | 0.010 |
Why?
| | Occupational Exposure | 1 | 2004 | 341 | 0.010 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2002 | 195 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 2003 | 433 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 2139 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 852 | 0.010 |
Why?
| | Swine | 1 | 2002 | 775 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 984 | 0.010 |
Why?
| | Aorta | 1 | 2002 | 417 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2003 | 746 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2900 | 0.010 |
Why?
| | Electrocardiography | 1 | 2002 | 629 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2002 | 739 | 0.010 |
Why?
| | Fatty Acids | 1 | 2002 | 443 | 0.010 |
Why?
| | Estradiol | 1 | 2002 | 521 | 0.010 |
Why?
| | Survival Rate | 1 | 2003 | 1972 | 0.010 |
Why?
| | Fetus | 1 | 2003 | 806 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2002 | 718 | 0.010 |
Why?
| | Calcium | 1 | 2002 | 1199 | 0.010 |
Why?
| | Kidney | 1 | 2003 | 1468 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3566 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2010 | 15657 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2002 | 1724 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2003 | 6079 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2253 | 0.010 |
Why?
|
|
Day's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|